MaxCyte Inks Multi-Platform License Deal with Genentech to Boost Cell Therapy Development
MXCT sits 89% above its 52-week low of $0.643.
Summary
MaxCyte signed a technology license partnership with Genentech, a Roche unit, granting access to its ExPERT GTx platform and additional technologies across research, clinical, and manufacturing workflows. The deal is structured to support multiple cell therapy programs, deepening MaxCyte's relationship with a top-tier biopharma partner. This follows a period of financial stabilization, including a $10M buyback and a 54% net loss reduction in Q1. The partnership validates MaxCyte's platform and could drive recurring revenue from a major player, though financial terms were not disclosed. Watch for potential milestone payments or program updates that could quantify the deal's impact.
At the time of this announcement, MXCT was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.3M. The 52-week trading range was $0.64 to $2.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.